Sputnik V ( sputnik vaccine )

 Sputnik V ( sputnik vaccine )

GENERAL INFORMATION

Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 65 countries.

The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers. Phase 3 clinical trials of Sputnik V have been conducting in the UAE, India, Venezuela and Belarus.

Sputnik V is one of the three vaccines in the world with efficacy of over 90%. The Vaccine’s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6% efficacy.

RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two dose vaccine). The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.

The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

• Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;

• The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;

• Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;

• The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;

• No serious adverse events were registered after vaccination with Sputnik Light.